The determinants of the antibiotic resistance process

Infection and Drug Resistance

Volumn 2, Issue 1, 2009, Pages 1-11

  Franco, Beatriz Espinosa ^a   Martínez, Marina Altagracia ^b   Sánchez Rodríguez, Martha A ^a   Wertheimer, Albert I ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Antibiotic drug resistance; Determinants; Social biological

Indexed keywords

ANTIBIOTIC AGENT; CEFTERA; CEFTOBIPROLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; DOXYCYCLINE; ERTAPENEM; FROPENEM; ICLAPRIM; LINEZOLID; ORITAVANCIN; PRISTINAMYCIN; STREPTOGRAMIN; SULFAMIDOCHRYSOIDINE; SULFONAMIDE; TEICOPLANIN; TELAVANCIN; TELITHROMYCIN; TIGECYCLINE; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CATHETER INFECTION; CLINICAL RESEARCH; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; LIVER TOXICITY; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PATIENT EDUCATION; PRESCRIPTION; PRIVATE HOSPITAL; PSYCHOLOGICAL ASPECT; PUBLIC HOSPITAL; PYELONEPHRITIS; REVIEW; SKIN INFECTION; SOCIAL ASPECT; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; UNCONSCIOUSNESS; URINARY TRACT INFECTION; VISUAL DISORDER;

EID: 77953469042     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Grupo Colaborativo Resist Net. La resistencia a los antibióticos en América Latina: importancia de los programas Artemio y Resist Net. In: Salvatierra-González R, Benguigui Y, editors. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. 39-53.
2. Sader HS, Jones RN. Resistencia a los antimicrobianos de los agentes patógenos causantes de infecciones nosocomiales y comunitarias en América Latina: reseña general de las estadísticas de 1997. In: Salvatierra-González R, Benguigui Y, editors. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. 54-73.
3. Fefer E. Uso racional de medicamentos: políticas, reglamentación y normas regionales. In: Salvatierra-González R, Benguigui Y, editors. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. 211-219.
4. Murray BE. Problemas y dificultades para controlar el uso de antibióticos. In: Salvatierra-González R, Benguigui Y, editors. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. 220-227.
5. Almeida FN. For a general theory of health: preliminary epistemological and anthropological notes. Cad Saúde Pública, Rio de Janeiro. 2001;17(4):753-799.
6. Rodríguez RS. Consumo de antimicrobianos en el hospital: costos y consecuencias del uso y abuso. In: Salvatierra-González R, Benguigui Y, editors. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. 246-257.
7. Overbye KM, Barrett JF. Antibiotics: where did we go wrong? DDT. 2005;10(1):45-52.
8. Harbarth S, Samore MH. Antimicrobial resistance determinants and future control. Emerg Infect Dis. 2005;11(6):794-801. (Pubitemid 40720837)
9. Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Manage. 2001;42:183-206. (Pubitemid 34124508)
10. Vázquez-Moreno E, Moreno-Santamaría R, Altagracia- Martínez M, Kravzov-Jinich J, Ríos-Castañeda C. Self-medication in the Mexican State of Veracruz. J Pharm Finance, Economics and Policy. 2004;13(2):45-63.
11. Altagracia-Martínez M, Kravzov-Jinich J, Moreno-Santamaría R, Ríos-Castañeda C, Vázquez-Moreno E. Automedicación en comunidades rural y urbanas del Estado de Guerrero, México. Revista Mexicana de Ciencias Farmacéuticas. 2003;34(2):27-35.
12. Dreser A, Wirtz VJ, Corbett KK, Echániz G. Uso de antibióticos en México: revisión de problemas y políticas. Salud Pública Méx. 2008;50(4):480-487.
13. Kogut SJ, Spooner LM. Resistance to in-offi ce dispensing of generic antibiotic samples. J Manag Care Pharm. 2009;15(1):62-65.
14. Conklin MH, Culley EJ, O'Donnell J. Case study of the effects of offi cebased generic drug sampling on antibiotic drug costs and fi rst-line antibiotic prescribing ratios. J Manag Care Pharm. 2009;15(1):55-61.
15. Scott AB, Culley EJ, O'Donnell J. Effects of a physician office generic drug sampling system on generic dispensing ratios and drug costs in a large managed care organization. J Manag Care Pharm. 2007;13(5):412-419. (Pubitemid 47162415)
16. Zhang Y, Harvey K. Rational antibiotic use in China: lessons learnt through introducing surgeons to Australian guidelines. Aust New Zealand Health Policy. 2006;3(5):1-6.
17. Norrby SR, Nord CE, Finch Roger. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 2005;5:115-119.
18. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36(1):1433-1437.
19. Larson E, Lin SX, Gomez-Duarte C. Antibiotic use in Hispanic households, New York City. Emerg Infect Dis. 2003;9(9):1096-1102.
20. Use of antimicrobials outside human medicine and resultant antimicrobial resistance in humans. World Health Organization. 2002 [cited 2005 Aug 24]; 268: [about 4 p.]. Available from: http://www.who.int/mediacentre/factsheets/fs268/ en/print.html.
21. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman GA, editors. Las bases farmacológicas de la terapéutica. 9th ed. México, DF: McGraw-Hill Interamericana; 2000. p. 1095-1121.
22. Salvatierra-González R, Benguigui Y. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. vii-xi.
23. Tortora JG. Microbiology: an introduction. 7th ed. Redwood City, CA: The Benjamín Cummin Publishing Company; 2001. p. 491-509.
24. Stuart TW. Microbiología. 6a ed. Madrid, Spain: McGraw-Hill Interamericana; 2000. p. 79-111.
25. Black GJ. Microbiology principles and applications. 6th ed. New Jersey, Upper Saddle River, NJ: Prentice Hall; 2004. p. 356-372.
26. Ingraham JL, Ingraham CA. Introducción a la microbiología. 2nd ed. Barcelona, Spain: Reverté; 2002. p. 486-513.
27. Joklik KW, Willett PH, Amos B. Microbiología Zinsser. 20th ed. Buenos Aires, Argentina: Editorial Médica Panamericana; 1998. p. 219-228.
28. Romero CR. Microbiología y parasitología humana. 2nd ed. México, DF: Editorial Médica Panamericana; 1996. p. 40-50.
29. Heinemann JA. How antibiotics cause antibiotic resistance. DDT. 1999;4:72-79.
30. Kunin CM. Resistance to antimicrobial drugs-a worldwide calamity. Ann Inter Medic. 1993;118(7):557-561.
31. McCormick JB. Epidemiology of emerging/re-emerging antimicrobialresistant bacterial pathogens. Curr Opin Microbiol. 1998;1:125-129.
32. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005;18(4):638-656.
33. Barie PS, Dellinger EP, Ellner JJ, McGowan JE. Maximizing nosocomial infection management with newer therapeutic approaches and techniques in an era of increasing microbial resistance: a surgical perspective. 2007; [cited 2007 Sept 22]; [about 15 p.]. Available from: http://www.medscape.com/viewprogram/ 7566-pnt.
34. Walsh C. Antibiotics: actions, origins, resistance. Washington, DC: ASM Press; 2003. p. 3-20, 285-295.
35. Capriotti T. Resistant "superbugs" create need for novel antibiotics. Dermatol Nurs. 2007;19(1):65-70.
36. Lopez LP, Li JZ, Balan DA, et al. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infection among hospitalized patients from South America and Mexico: results from a multicenter trial. Clin Ther. 2003;25(6):1846-1871
37. Final labeling. Synercid® I.V. [cited 2008 Jun 18]; [about 16 p.]. Available from: http://www.fda.gov/cder/foi/label/2008/050748s008,050747s008lbl. pdf.
38. Wright GD. Mechanisms of resistance to antibiotics. Curr Opin Chem Biol. 2003;7:563-569.
39. Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections, caused by Gram-positive bacteria. Curr Opin Microbiol. 2005;8:510-517.
40. Food and Drug Administration. Index to Drug-Specifi c Information. 2009 [cited 2009 Feb 18] Available from: http://www.fda.gov/cder/drug/DrugSafety/ DrugIndex.htm.
41. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy. 2007;27(2):227-249.
42. Final labeling. Daptomycin (Cubicin® ) I.V. [cited 2003 Dec 13]; [about 1 p.]. Available from: http://www.fda.gov/cder/drug/InfoSheets/patient/ daptomycinPIS.htm.
43. Final labeling. Tigecycline (Tygacil® ) I.V. [cited 2005 July 27]; [about 1 p.]. Available from: http://www.fda.gov/cder/drug/InfoSheets/patient/ tigecyclinePIS.htm.
44. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother. 1994;38(7):1658-1660.
45. FDA alert, Linezolid (Zyvox® ). Information. [cited 2007 Mar 16]; [about 1 p.]. Available from: http://www.fda.gov/cder/drug/infopage/linezolid/ default.htm.
46. Telithromycin (Ketek® ). Information. [cited 2007 Feb 12]; [about 1 p.]. Available from: http://www.fda.gov/cder/drug/infopage/telithromycin/ default.htm.
47. Application number: 21-337. Ertapenem (Invanz® ) I.V. or I.M. [cited 2001 Nov 21]; [about 1 p.]. Available from: http://www.fda.gov/cder/foi/nda/ 2001/21337-Invanz-prntlbl.pdf.
48. FDA approves new drug to treat complicated urinary tract and intraabdominal infections. [cited 2007 Oct 17]; [about 1 p]. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01728.html.
49. Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N. National and regional assessment of antimicrobial resistance among community - acquired respiratory tract pathogens identified in a 2005-2006 US faropenem surveillance study. Antimicrob Agents Chemother. 2007;51(12):4382-4389.
50. Jagusztyn-Krynicka EK, Wyszyńska A. The decline of antibiotic era-new approaches for antibacterial drug discovery. Pol J Microbiol. 2008;57(2):91-98.
51. Ertapenem (INVANZ)-A new parenteral carbapenem. The Medical Letter. 2002;44(W1126A):25-26.
52. Levy SB. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother. 2002;49(1):25-30. (Pubitemid 34100643)
53. World Health Organization (WHO). Drug resistance threatens to reverse medical progress. Press Release WHO/41.2000; [cited 2005 Aug 24]; [about 4 p.]. Available from: http://www.essentialdrugs.org/efarmacos/archive/200011/msg00040. php.
54. Colgan R, Powers JH. Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance. Am Fam Physician. 2001;64(6):999-1004. (Pubitemid 32900287)
55. Andersson DI. Persistence of antibiotic resistant bacteria. Curr Opini Microbiol. 2003;6:452-456.
56. Mckeegan KS, Borges-Walmsley MI, Walmsley AR. Microbial and viral drug resistance mechanisms. Trends Microbiol. 2002;10(10):S8-S14.
57. Cantrell R, Young AF, Martin BC. Antibiotic prescribing in ambulatory care settings for adults with colds, upper respiratory tract infections, and bronchitis. Clin Ther. 2002;24(1):170-182. (Pubitemid 34117532)
58. Cassell GH. Emergent antibiotic resistance: health risks and economic impact. FEMS Immunol Med Microbiol. 1997;18:271-274.
59. Lipsitch M. The rise and fall of antimicrobial resistance. Trends Microbiol. 2001;9(9):438-442.
60. Wise R, Hart T, Cars O, et al. Antimicrobial resistance. BMJ. 1998;317(7159):609-610.
61. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat. 2000;3:303-311.
62. Jacobs MR. Streptococcus pneumoniae: Epidemiology and patterns of resistance. Am J Med. 2004;117(3A):3S-15S.
63. Bergoglio RM. Antibióticos. 5th ed. Buenos Aires, Argentina: Editorial Médica Panamericana; 1993. p. 3-95.
64. Mascaretti OA. Bacteria versus antibacterial agents an integrated approach. Washington, DC: ASM Press; 2003. p. 87-95.
65. Rooklidge SJ. Environmental antimicrobial contamination from terraccumulation and diffuse pollution pathways. Sci Total Environ. 2004;325:1-13.
66. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC. Diagnóstico Microbiológico. 5th ed. Buenos Aires, Argentina: Editorial Panamericana; 1999. p. 764-832.
67. Whittle G, Shoemaker NB, Salyers AA. The role of bacteroides conjugative transposons in the dissemination of antibiotic resistance genes. Cell Mol Life Sci. 2002;9(12):2044-2054. (Pubitemid 36140277)
68. Poole K. Multidrug resistance in Gram-negative bacteria. Curr Opin Microbiol. 2001;4(5):500-508.
69. Davis BD, Dulbecco R, Eisen HN, Ginsberg HS, editors. Tratado de Microbiología. 4th ed. Barcelona, Spain: Masson S.A; 1996. p.198-219.
70. Domínguez E, Zarazaga M, Saenz Y, Brinas L, Torres C. Mechanisms of antibiotic resistance in Escherichia coli isolates obtained from healthy children in Spain. Microb Drug Resist. 2002;8(4):321-327. (Pubitemid 36043698)
71. Hogan D, Kolter R. Why are bacteria refractory to antimicrobials? Curr Opin Microbiol. 2002;5:472-477.
72. Sander CC, Sander WE. Resistance to antibacterial agent. In: Jung Kind DL, Mortensen JE, Fraimoro HS, Calandra GB, editors. Antimicrobial resistance: A crisis in health care. New York, NY: Plenum Press; 1995. p. 15-23.
73. Harbarth S, Albrich W, Brun-Buisson C. Outpatient antibiotic use and prevalence of antibiotic-resistant Pneumococci in France and Germany: a sociocultural perspective. Emerg Infect Dis. 2002;8(12):1460-1467. (Pubitemid 36008785)
74. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother. 2003;52:11-17. (Pubitemid 36850078)
75. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis. 2002;185:561-565. (Pubitemid 34142821)
76. Drlica K. Antibiotic resistance: can we beat the bugs? DDT. 2001;6(14):714.
77. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis. 2007;44(5):681-688. (Pubitemid 46272977)
78. Kozyrskyj AL, Dahl ME, Chateau DG, Mazowita GB, Klassen TP, Law BJ. Evidence-based prescribing of antibiotics for children: role of socioeconomic status and physician characteristics. CMAJ. 2004;171(2):139-145.
79. Nicolle LE. Preventing infections in non-hospital settings: long-term care. Emerg Infect Dis. 2001;7(2):205-207. (Pubitemid 32374329)
80. Butler CC, Kinnersley P, Prout H, Rollnick S, Edwards A, Elwyn G. Antibiotics and shared decision-making in primary care. J Antimicrob Chemother. 2001;48:435-440. (Pubitemid 32898819)
81. Arias ML, Artavia J, González P, Monge R. Antimicrobial susceptibility pattern of Gram-negative bacterias isolated from enteral feeding. Rev Biomed. 2000;11(3):169-174.
82. Gómez-Barreto D, Calderón-Jaimes E, Rodríguez R, Espinosa ML, Juárez M. características clínico- microbiológicas de la meningitis por Streptococcus pneumoniae resistente a la penicilina. Salud Pública Mex. 1999;41(5):397-404.
83. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili Sh, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43-48. (Pubitemid 43042900)
84. Bartlett JG. Literatura Commentary by John G. Bartlett: Antibiotic resistance. 2007; [cited 2007 July 20]; [about 3 p.]. Available from: http://www.medscape.com.
85. Coenen S, Michiels B, Van Royen P, Van der Auwera JC, Denekens J. Antibiotics for coughing in general practice: a questionnaire study to quantify and condense the reasons for prescribing. BMC Fam Pract. 2002;3(16):1-10. (Pubitemid 38994225)
86. Linder JA, Singer DE, Stafford RS. Association between antibiotic prescribing and visit duration in adults with upper respiratory tract infections. Clin Ther. 2003;25:2419-2430. (Pubitemid 37267249)
87. Owens RC, Fraser GL, Stogsdill P. Antimicrobial stewardship programs as a means to optimize antimicrobial use. Pharmacotherapy. 2004;24(7):896-908.
88. Pedersen G, Schonheyder HC, Steffensen FH, Sorensen HT. Risk of resistance related to antibiotic use before admission in patients with community-acquired bacteraemia. J Antimicrob Chemother. 1999;43:119-126. (Pubitemid 29045940)
89. Bauchner H, Simpson L, Chessare J. Changing physician behaviour. Leading articles. Arch Dis Child. 2001;84:459-462.
90. Antimicrobial resistance. World Health Organization. 2002; [cited 2005 Aug 24]; 194: [about 4 p.]. Available from: http://www.who.int/mediacentre/ factsheets/fs194/en/print.html.
91. Arias IB, Meza AL. Resistencia antimicrobiana de Salmonella, Shigella y Vibrio cholerae, Perú 1997-2002. Rev Peru Med Exp Salud Publica. 2004;21(4):273-275.
92. Van Driel ML, De Shutter A, Deveugele M, et al. Cristianes T. Are sore throat patients who hope for antibiotics actually asking for pain relief? Ann Fam Med. 2006;4(6):494-499. (Pubitemid 44916073)
93. Metlay JP, Branas ChC, Fishman NO. Hospital-reported Pneumococcal susceptibility to penicillin. Emerg Infect Dis. 2004;10(1):54-59.
94. Balabanova Y, Fedorin I, Kuznetsov S, et al. Antimicrobial prescribing patterns for respiratory diseases including tuberculosis in Russia: a possible role in drug resistance? J Antimicrob Chemother. 2004;54:673-679. (Pubitemid 39263910)
95. Castro R. Sicología Médica en México: el último cuarto de siglo. Rev Mex Sociol. 2001;63(3):271-293.
96. Smith RD, Coast J. Antimicrobial resistance: a global response. Bull World Health Organ. 2002;80:126-133.
97. Kravits R. Measuring patients' expectations and requests. Ann Intern Med. 2001;134:881-888.
98. Matuz M, Benko R, Doro P, Hajdu E, Nagy G, Nagy E, Monnet DL, Soos G. Regional variations in community consumption of antibiotics in Hungary, 1996-2003. Br J Clin Pharmacol. 2005;61(1):96-100.
99. Wegener HC, Aarestrup FM, Jensen LG, Hammerum AM, Bager F. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerg Infect Dis. 1999;5(3):329-335. (Pubitemid 29289446)
100. Lovine NM, Blazer MJ. Antibiotics in animal feed and spread of resistant Campylobacter from poultry to humans. Emerg Infect Dis. 2004;10(6):1158-1159.
101. Angulo FJ, Nunnery JA, Bair HD. Antimicrobial resistance in zoonotic enteric pathogens. Rev Sci Tech Off Int Epiz. 2004;23(2):1-12.
102. Anderson AD, Nelson JM, Rossiter Sh, Angulo FJ. Public health consequences of use of antimicrobial agents in food animals in the United States. Microb Drug Resist. 2003;9:373-379.
103. Gerst J. Detección de la resistencia a los antibióticos con los sistemas Vitek y Vitek 2 de bioMérieux. In: Salvatierra- González R, Benguigui Y, editors. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. 12-23.
104. Dancer SJ. How antibiotics can make us sick: the less obvious adverse effects of antimicrobial chemotherapy. Lancet Infect Dis. 2004;4:611-619.
105. Cabello FC. Antibióticos y acuicultura en Chile: consecuencias para la salud humana y animal. Rev Med Chile. 2004;132:1001-1006.
106. Gay K, Baughman W, Millar Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis. 2000;182:1417-1424.
107. Zoutman DE, Ford BD. The relationship between hospital infection surveillance and control activities and antibiotic-resistant pathogen rates. Am J Infect Control. 2005;33(1):1-5.
108. Sifuentes-Osornio J y Donís-Hernández J. Las redes de estudio de la resistencia bacteriana ¿son realmente necesarias? In: Salvatierra-González R, Benguigui Y, editors. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. 8-11.
109. Sosa A. La alianza para el uso prudente de los antibióticos. Resistencia a los antibióticos en América Latina. In: Salvatierra-González R, Benguigui Y, editors. Resistencia antimicrobiana en las Américas: Magnitud del problema y su contención. Washington, DC: OPS/OMS; 2000. p. 258-260.
110. Breilh J. Nuevos conceptos y técnicas de Investigación. Guía pedagógica para un taller de metodología. Quito, Ecuador: Centro de Estudios y Asesoría en Salud; 1994. p. 19-57.
111. Avorn JL, Barrett JF, McEwen SA, O'Brien TF, Levy SB. Antibiotic resistance synthesis of recommendations by expert policy groups. Geneva, Switzerland; World Health Organization; 2001. p. 1-163
112. Madaras-Kelly K. Optimizing antibiotic use in hospitals: the role of population-based antibiotic surveillance in limiting antibiotic resistance. Pharmacotherapy. 2003;23(12):1627-1633.
113. Gleckman RA. Selected issues in antibiotic resistance. Infect Med. 2004;21(3):114-122.
114. Zaidi M, Sifuentes-Osornio J, Rolón AL, et al. Inadequate therapy and antibiotic resistance risk factors for mortality in the intensive care unit. Arch Med Res. 2002;33(3):290-294. (Pubitemid 34553357)
115. Gotfried MH. Epidemiology of clinically diagnosed communityacquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am J Med. 2001;111(9A):25S-29S.
116. Finkelstein JA, Davis RL, Dowell SF, et al. reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics. 2001;108(1):1-7.
117. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31(Suppl 4):S131-S138.
118. Courvalin P. Antimicrobial drug resistance: "prediction is very diffi cult, especially about the future". Emerg Infect Dis. 2005;11(10):1503-1506.
119. Andrés JC, Andrés NF, Fornos JA. Evaluación de la intervención farmacéutica sobre cumplimiento en terapia antibiótica. Seguim Farmacoter. 2004;2(2):97-102.